Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,113 matching trials from the live ClinicalTrials.gov search.

Filters: Fullerton, California Clear all

Conditions: Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo (for Ramucirumab), Docetaxel; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 97
States / cities: Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more

Conditions: Pancreatic Neoplasms, Metastases, Neoplasm
Interventions: GEMZAR, ALIMTA; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 40
States / cities: Huntsville, Alabama • Fountain Valley, California • Fullerton, California + 37 more

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more

Conditions: Ovarian Cancer
Interventions: INCB123667, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 63
States / cities: Anchorage, Alaska • Tucson, Arizona • Duarte, California + 56 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 110
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 94 more

Conditions: Overweight, Obesity
Interventions: zenagamtide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 41
States / cities: Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 36 more

Conditions: Coronavirus Disease 2019
Interventions: Placebo, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more

Conditions: Breast Cancer, Renal Cell Carcinoma
Interventions: IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 24
States / cities: Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more

Conditions: Breast Neoplasm, Neoplasm Metastasis
Interventions: Abemaciclib, Fulvestrant, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 60
States / cities: Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more

Conditions: Breast Neoplasms
Interventions: SU011248, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 77
States / cities: Corona, California • Fullerton, California • Glendora, California + 59 more

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more

Conditions: Metastatic Malignant Neoplasm in the Brain
Interventions: Single Fraction Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 223
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 180 more

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more

Conditions: Myasthenia Gravis
Interventions: Nipocalimab, Efgartigimod; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Fullerton, California • Pomona, California • Colorado Springs, Colorado + 17 more

Conditions: Maxillary Sinus Bone Loss
Interventions: INFUSE® Bone Graft; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Fullerton, California • Denver, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib, Fulvestrant, Standard Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 55
States / cities: Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more

Conditions: Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas, Cancer of the Pancreas, Metastases, Metastatic Cancer, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Cancer, Bone Metastases, Endocrine Cancer, Oncology, Oncology Patients, Solid Tumors, Advanced Malignancy
Interventions: AMG 479, Placebo, gemcitabine; Drug
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 24
States / cities: Fullerton, California • La Jolla, California • Los Angeles, California + 18 more

Conditions: Cachexia, Non-Small Cell Lung Cancer
Interventions: Anamorelin HCl, Placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 19
States / cities: Corona, California • Fountain Valley, California • Fullerton, California + 16 more

Conditions: Breast Cancer
Interventions: PD 0332991, letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 51
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 24 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 42
States / cities: Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more

Conditions: Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions: Atezolizumab, Bevacizumab, Computed Tomography, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment; Drug · Biological · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 907
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more

Conditions: Malignant Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Not listed
Enrollment: 999,999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2033
U.S. locations: 35
States / cities: Phoenix, Arizona • Concord, California • Duarte, California + 29 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 9,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 91
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Searcy, Arkansas + 79 more

Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions: FT819, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 16
States / cities: Beverly Hills, California • Fullerton, California • Irvine, California + 13 more

Search by objective public record fields.

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Sinus Augmentation With Dental Implant

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Molecular Genetics Studies of Cancer Patients and Their Relatives

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease